| Literature DB >> 34064950 |
Leen A Aldwihi1, Shahd I Khan1,2, Faisal F Alamri3,4, Yazed AlRuthia1,5, Faleh Alqahtani6, Omer I Fantoukh7, Ahmed Assiri8, Omar A Almohammed1.
Abstract
The use of traditional medicinal plants in Saudi Arabia stems mainly from consumers' belief in prophetic medicine. This study was conducted to explore changes in patients' use of dietary or herbal supplements among individuals infected with COVID-19 before and during infection and the association between herbal or dietary supplements and hospitalization. A cross-sectional, questionnaire-based study was conducted enrolling symptomatic patients who had recently recovered from COVID-19. Data were collected through phone interviews, and McNemar's test was used to investigate changes to consumption of dietary or herbal supplements before and during infection. Multivariable logistic regression was used to investigate the association between supplements use during patients' infection and hospitalization. A total of 738 patients were included in this study, of whom 32.1% required hospitalization. About 57% of participants were male with a mean age of 36.5 (±11.9) years. The use of lemon/orange, honey, ginger, vitamin C, and black seed among participants significantly increased during their infection. In contrast, patients using anise, peppermint, and coffee peel before their infection were more likely to stop using them during their infection. In addition, using lemon/orange (p < 0.0001), honey (p = 0.0002), ginger (p = 0.0053), vitamin C (p = 0.0006), black seed (p < 0.0001), peppermint (p = 0.0027), costus (p = 0.0095), and turmeric (p = 0.0012) was significantly higher among nonhospitalized patients than hospitalized ones. However, in the multivariable logistic regression, only use of vitamin C (OR = 0.51; 95% CI 0.33-0.79), peppermint (OR = 0.53; 95% CI 0.31-0.90), and lemon/orange (OR = 0.54; 95% CI 0.33-0.88) was associated with significantly lower odds of hospitalization. The study reveals that patients' consumption of dietary or herbal supplements changed in response to their COVID-19 infection, with hospitalized patients having a lower likelihood of using these supplements. Because some supplements were associated with lower odds of hospitalization, these supplements or their bioactive components should be further investigated as feasible options for COVID-19 treatment.Entities:
Keywords: COVID-19; Saudi Arabia; behavior; dietary; herbal; hospitalization; supplements
Mesh:
Year: 2021 PMID: 34064950 PMCID: PMC8151200 DOI: 10.3390/ijerph18105086
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Patient demographics.
| Variables | Overall, Sample | Nonhospitalized | Hospitalized | |
|---|---|---|---|---|
|
| 36.5 (11.9) | 33.6 (10.2) | 42.4 (12.9) |
|
|
| 28.4 (7.1) | 27.3 (7.1) | 30.6 (6.8) |
|
|
| - | - | - | - |
|
| 418 (56.6) | 286 (68.4) | 132 (31.6) | 0.7542 |
|
| 320 (43.4) | 215 (67.2) | 105 (32.8) | - |
|
| - | - | - | - |
|
| 559 (75.7) | 409 (73.2) | 150 (26.8) |
|
|
| 179 (24.3) | 92 (51.4) | 87 (48.6) | - |
|
| - | - | - | - |
|
| 199 (27.0) | 168 (84.4) | 31 (15.6) |
|
|
| 500 (67.8) | 312 (62.4) | 188 (37.6) | - |
|
| 26 (3.5) | 18 (69.2) | 8 (30.8) | - |
|
| 13 (1.7) | 3 (23.1) | 10 (76.9) | - |
Data presented as frequency (%) unless otherwise indicated. * p-values were from t-test for continuous data (age and BMI) and chi-squared test for categorical data.
Change in patients’ use of dietary or herbal supplements before and during infection with COVID-19.
| Dietary or Herbal Supplements | Supplement Consumption before COVID-19 Infection | Supplement Consumption during COVID-19 Infection | Change in Use from before to during COVID-19 Infection | |||
|---|---|---|---|---|---|---|
| Yes | No | Yes | No | |||
|
| 267 (36.2) | 471 (63.8) | 425 (57.6) | 313 (42.4) | 158 (21.4%) |
|
|
| 146 (19.8) | 592 (80.2) | 168 (22.8) | 570 (77.2) | 22 (3.0%) |
|
|
| 82 (11.1) | 656 (88.9) | 77 (10.4) | 661 (89.6) | −5 (−0.7%) | 0.5529 |
|
| 54 (7.3) | 684 (92.7) | 51 (6.9) | 687 (93.1) | −3 (−0.4%) | 0.6911 |
|
| 260 (35.2) | 478 (64.8) | 161 (21.8) | 577 (78.2) | −99 (−13.4%) |
|
|
| 74 (10.0) | 664 (90.0) | 50 (6.7) | 688 (93.2) | −24 (−3.3%) |
|
|
| 368 (49.9) | 370 (50.1) | 591 (80.1) | 147 (19.9) | 223 (30.2%) |
|
|
| 320 (43.4) | 418 (56.6) | 524 (71.0) | 214 (29.0) | 204 (27.6%) |
|
|
| 145 (19.6) | 593 (80.4) | 345 (46.8) | 393 (53.2) | 200 (27.1%) |
|
|
| 17 (2.3) | 721 (97.7) | 115 (15.6) | 623 (84.4) | 98 (13.3%) |
|
|
| 231 (31.3) | 507 (68.7) | 271 (36.7) | 467 (63.3) | 40 (5.4%) |
|
|
| 360 (48.8) | 378 (51.2) | 505 (68.4) | 233 (31.6) | 145 (19.6%) |
|
|
| 255 (34.6) | 483 (65.4) | 259 (35.1) | 479 (64.9) | 4 (0.5%) | 0.7335 |
Data presented as frequency (%); * p-value from McNemar’s test.
Change in patients’ behavior during infection with COVID-19 for previous consumers or nonconsumers of dietary or herbal supplements before infection.
| Natural Product or Supplement | When Had COVID-19 | |
|---|---|---|
| Avoided Use of Supplement ‡ | Started Using Supplement | |
|
| 43 (16.1) | 201 (42.7) |
|
| 51 (34.9) | 73 (12.3) |
|
| 38 (46.3) | 33 (5.0) |
|
| 30 (55.6) | 27 (4.0) |
|
| 147 (56.5) | 48 (10.0) |
|
| 35 (47.3) | 11 (1.7) |
|
| 40 (10.9) | 263 (71.1) |
|
| 43 (13.4) | 247 (59.1) |
|
| 31 (21.4) | 231 (39.0) |
|
| 7 (41.2) | 105 (14.6) |
|
| 93 (40.3) | 133 (26.2) |
|
| 16 (4.4) | 161 (42.6) |
|
| 67 (26.3) | 71 (14.7) |
Data presented as frequency (%); ‡ patients who were using dietary or herbal supplement before they acquired COVID-19 but who avoided or did not use it afterward; patients who were not using dietary or herbal supplement before they acquired COVID-19 but who started using it afterward.
Association between use of dietary or herbal supplements during infection with COVID-19 and hospitalization for COVID 19 treatment, before and after adjustment in multivariate logistic regression analysis.
| Natural Product or Supplement | Patient Using Status during Infection | Nonhospitalized | Hospitalized | Odds Ratio (95%CI) † | |
|---|---|---|---|---|---|
|
| Nonuser | 195 (62.3) | 118 (37.7) |
| Reference |
| User | 306 (72.0) | 119 (28.0) | 1.06 (0.68–1.63) | ||
|
| Nonuser | 379 (66.5) | 191 (33.5) | 0.1349 | Reference |
| User | 122 (72.6) | 46 (27.4) | 1.11 (0.66–1.86) | ||
|
| Nonuser | 442 (66.9) | 219 (33.1) | 0.0827 | Reference |
| User | 59 (76.6) | 18 (23.4) | 1.08 (0.49–2.36) | ||
|
| Nonuser | 463 (67.4) | 224 (32.6) | 0.2937 | Reference |
| User | 38 (74.5) | 13 (25.5) | 1.43 (0.62–3.32) | ||
|
| Nonuser | 376 (65.2) | 201 (34.8) |
| Reference |
| User | 125 (77.6) | 36 (22.4) |
| ||
|
| Nonuser | 466 (67.7) | 222 (32.3) | 0.7402 | Reference |
| User | 35 (70.0) | 15 (30.0) | 1.39 (0.61–3.12) | ||
|
| Nonuser | 75 (51.0) | 72 (49.0) |
| Reference |
| User | 426 (72.0) | 165 (28.0) |
| ||
|
| Nonuser | 124 (57.9) | 90 (42.1) |
| Reference |
| User | 377 (72.0) | 147 (28.0) | 1.04 (0.64–1.70) | ||
|
| Nonuser | 241 (61.3) | 152 (38.7) |
| Reference |
| User | 260 (75.4) | 85 (24.6) | 0.66 (0.42–1.05) | ||
|
| Nonuser | 411 (66.0) | 212 (34.0) |
| Reference |
| User | 90 (78.3) | 25 (21.7) | 0.61 (0.33–1.12) | ||
|
| Nonuser | 312 (66.8) | 155 (33.2) | 0.4108 | Reference |
| User | 189 (69.7) | 82 (30.3) | 1.11 (0.70–1.69) | ||
|
| Nonuser | 387 (65.2) | 207 (34.8) |
| Reference |
| User | 114 (79.2) | 30 (20.8) | 0.59 (0.33–1.06) | ||
|
| Nonuser | 355 (65.9) | 184 (34.1) | 0.0527 | Reference |
| User | 146 (73.4) | 53 (26.6) | 0.68 (0.41–1.13) | ||
|
| Nonuser | 138 (59.2) | 95 (40.8) |
| Reference |
| User | 363 (71.9) | 142 (28.1) |
| ||
|
| Nonuser | 336 (70.2) | 143 (29.8) | 0.0737 | Reference |
| User | 165 (63.7) | 94 (36.3) |
|
Data presented as frequency (%); * p-value from chi-squared tests; † odds ratio from multivariate logistic regression with 95% confidence interval; the dependent variable in the logistic regression model was the need for hospitalization, and the results from the model were adjusted for the effects of age, gender, BMI, marital status, and the presence of any of the following comorbid conditions: diabetes, hypertension, dyslipidemia, pulmonary diseases (e.g., asthma, COPD), cardiovascular diseases, chronic kidney diseases, acquired immunodeficiency syndrome (AIDS), cancer, and depression or anxiety.